Kanjinti

NDC 55513-141 · Amgen, Inc

Generic nametrastuzumab-anns

Dosage formINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

RouteINTRAVENOUS

Active ingredient(s)TRASTUZUMAB

Strength150 mg/7.15mL

Pharmacologic classHER2/Neu/cerbB2 Antagonists [MoA], HER2/neu Receptor Antagonist [EPC]

Marketing categoryBLA

Packages

55513-141-01 — 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-141-01) / 7.15 mL in 1 VIAL, SINGLE-DOSE

55513-141-21 — 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-141-21) / 7.15 mL in 1 VIAL, SINGLE-DOSE

Billed under HCPCS

Q5117 — Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg Medicare Part B payment limit (ASP + 6%): $60.52

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

0069-0308 — trastuzumab-qyyp, 50242-077 — Trastuzumab and hyaluronidase-oysk, 50242-132 — Trastuzumab, 50242-245 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-260 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 55513-132 — trastuzumab-anns, 63459-303 — TRASTUZUMAB, 67457-991 — trastuzumab, 78206-147 — trastuzumab, 83257-001 — trastuzumab-dkst, 83257-003 — trastuzumab-dkst

From the FDA National Drug Code Directory, retrieved 2026-08-24. Product listings are submitted by labelers; FDA does not verify them.